详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Biomedical Sciences, JCC College of Veterinary Medicine and Life Science, City University of Hong Kong, Hong Kong SAR, China. [2]CityU Shenzhen Research Institute, Shenzhen, China. [3]Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE and State Key Laboratory of Biotherapy, West China Second Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, 610041, Sichuan, P. R. China [4]The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P. R. China [5]Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P. R. China

出处：

DOI：

摘要：

It is still a big puzzle how ovarian cancer cells and the tumor microenvironment (TME) attract lymphocytes infiltration for facilitating metastasis, a leading cause of death from gynecological malignancies. Using genome-wide LncRNA microarray assay, here we report that a LncRNA associated with ovarian cancer metastasis (LncOVM) is highly correlated with poor prognosis and survival. LncOVM interacts with and stabilizes PPIP5K2 by suppressing ubiquitinated degradation to promote complement C5 secretion from ovarian cancer cells. The TME-enriched complement C5 attracts myeloid-derived suppressor cells (MDSCs) infiltration in TME to facilitate metastasis. Knockdown of LncOVM or PPIP5K2 inhibits tumor progression in xenograft models. Application of C5aR antibody or inhibitor (CCX168) inhibits MDSC recruitment and restores the suppression of tumorigenesis and metastasis in vivo. Our study reveals that suppression of ovarian cancer metastasis can be achieved by targeting MDSC infiltration in TME through disrupting LncOVM-PPIP5K2-complement axis, providing an option for treating ovarian cancer patients.© The author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区生物学

小类 | 2 区生化与分子生物学

最新[2023]版：

大类 | 2 区

生物学

小类 | 2 区生化与分子生物学

第一作者：

第一作者机构： [1]Department of Biomedical Sciences, JCC College of Veterinary Medicine and Life Science, City University of Hong Kong, Hong Kong SAR, China. [2]CityU Shenzhen Research Institute, Shenzhen, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Biomedical Sciences, JCC College of Veterinary Medicine and Life Science, City University of Hong Kong, Hong Kong SAR, China. [2]CityU Shenzhen Research Institute, Shenzhen, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：